Phytopharm strikes deal for Chinese memory program

Phytopharm has struck a licensing deal with The Beijing Institute for its lead program for memory and concentration. The institute has a library of compounds based on traditional Chinese medicine. No financial terms were released.

- read the report from Hemscott

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.